Vir Biotechnology News and Activities

Vir Biotechnology is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Vir Biotechnology is a company listed under the stock ticker VIR (US).

View the org chart displaying its 31 main executives

Most searched biographies at Vir Biotechnology

• Marianne De Backer, Chief Executive Officer and Director
• Janet Napolitano, Director
• Timothy Coughlin, Director

Popular executive movements at Vir Biotechnology

• Timothy Coughlin has joined the company as Director  (posted on June 11 2026).

Create your alert
to follow the executive moves at Vir Biotechnology.

Vir Biotechnology has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Vir Biotechnology

• Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
• Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
• Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
• Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
• Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
• Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
• Vir Biotechnology to Participate in Upcoming Investor Conferences
• Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
• Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
• View more press releases Close

Social media about Vir Biotechnology

• Vir Biotechnology on Wikipedia, Google News & Yahoo Finance
• Vir Biotechnology on LinkedIn, X (Twitter) & YouTube